Dynamic Healthcare M&A Database

Acquiring Party	Meda AB (STO:MEDAA), a Swedish-based major specialty pharma company focussed on dermatology, respiratory, cardiology, pain and inflammation, and gastroenterology therapies.
Transferring Party	MedPointe Inc., a US-based specialty pharma focussed on allergy, respiratory and pain therapies.
Sector	Biopharmaceuticals
Date	August 22, 2007
Analysis Establishes Meda as a world-class specialty pharma company with full marketing coverage both in the US and Europe and with revenues approaching 1.4b. Provides Meda with an organizaton to market products in the US, while adding highly complementary, high growth product portfolios for distribution in Meda's core European markets. The companies had been collaborating for 5 years. Deal value -- $520.0m on sales of $196.0m (2.6x).
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 3Q07